Shares of Hypermarcas (OTCMKTS:HYPMY – Get Free Report) saw unusually-strong trading volume on Tuesday. 102,494 shares traded hands during mid-day trading, an increase of 117% from the previous session’s volume of 47,293 shares. The stock last traded at $5.36 and had previously closed at $5.14.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Hypermarcas presently has an average rating of “Buy”.
Read Our Latest Stock Report on Hypermarcas
Hypermarcas Price Performance
The company has a fifty day moving average of $4.63 and a 200 day moving average of $4.42. The firm has a market capitalization of $3.72 billion, a P/E ratio of 10.72 and a beta of 0.65. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26.
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a net margin of 19.77% and a return on equity of 12.68%. Sell-side analysts predict that Hypermarcas will post 0.51 earnings per share for the current year.
About Hypermarcas
Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.
Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.
The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.
See Also
- Five stocks we like better than Hypermarcas
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}